Dallah Healthcare 미래 성장

Future 기준 확인 3/6

Dallah Healthcare (는) 각각 연간 14.9% 및 11.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 14.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 17.2% 로 예상됩니다.

주요 정보

14.9%

수익 성장률

14.3%

EPS 성장률

Healthcare 수익 성장	15.5%
매출 성장률	11.9%
향후 자기자본 수익률	17.2%
애널리스트 커버리지	Good
마지막 업데이트	10 Dec 2024

최근 미래 성장 업데이트

Dallah Healthcare Company (TADAWUL:4004) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 14

Recent updates

With EPS Growth And More, Dallah Healthcare (TADAWUL:4004) Makes An Interesting Case

Dec 21

Some Shareholders Feeling Restless Over Dallah Healthcare Company's (TADAWUL:4004) P/E Ratio

Oct 31

The Return Trends At Dallah Healthcare (TADAWUL:4004) Look Promising

Oct 07

Do Dallah Healthcare's (TADAWUL:4004) Earnings Warrant Your Attention?

Sep 19

Dallah Healthcare Company (TADAWUL:4004) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 14

The Price Is Right For Dallah Healthcare Company (TADAWUL:4004)

Jul 18

Investors Will Want Dallah Healthcare's (TADAWUL:4004) Growth In ROCE To Persist

May 30

We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease

Apr 16

What You Can Learn From Dallah Healthcare Company's (TADAWUL:4004) P/E

Mar 18

Returns On Capital At Dallah Healthcare (TADAWUL:4004) Have Hit The Brakes

Feb 25

Dallah Healthcare (TADAWUL:4004) Has More To Do To Multiply In Value Going Forward

Oct 30

Dallah Healthcare (TADAWUL:4004) Is Reinvesting At Lower Rates Of Return

Jul 26

Returns On Capital Signal Tricky Times Ahead For Dallah Healthcare (TADAWUL:4004)

Apr 17

Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?

Feb 06

Dallah Healthcare (TADAWUL:4004) Will Want To Turn Around Its Return Trends

Dec 05

We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease

Nov 01

Industry Analysts Just Upgraded Their Dallah Healthcare Company (TADAWUL:4004) Revenue Forecasts By 10%

May 26

Calculating The Fair Value Of Dallah Healthcare Company (TADAWUL:4004)

May 20

Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching

Apr 16

Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively

Feb 03

Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?

Jan 10

Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively

Oct 19

Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively

Jul 09

Forecast: Analysts Think Dallah Healthcare Company's (TADAWUL:4004) Business Prospects Have Improved Drastically

Jun 16

Broker Revenue Forecasts For Dallah Healthcare Company (TADAWUL:4004) Are Surging Higher

May 02

What Kind Of Shareholders Hold The Majority In Dallah Healthcare Company's (TADAWUL:4004) Shares?

Mar 17

Has Dallah Healthcare (TADAWUL:4004) Got What It Takes To Become A Multi-Bagger?

Mar 02

Dallah Healthcare (TADAWUL:4004) Shareholders Booked A 45% Gain In The Last Year

Feb 15

Should You Buy Dallah Healthcare Company (TADAWUL:4004) For Its Dividend?

Feb 01

Are Dallah Healthcare's (TADAWUL:4004) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 05

Dallah Healthcare Company's (TADAWUL:4004) Intrinsic Value Is Potentially 26% Below Its Share Price

Dec 22

Will Dallah Healthcare (TADAWUL:4004) Multiply In Value Going Forward?

Nov 20

수익 및 매출 성장 예측

SASE:4004 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (SAR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	4,215	635	470	843	9
12/31/2025	3,843	521	314	685	9
12/31/2024	3,330	492	313	620	6
9/30/2024	3,203	471	358	779	N/A
6/30/2024	3,105	444	326	667	N/A
3/31/2024	3,010	385	415	724	N/A
12/31/2023	2,943	360	329	626	N/A
9/30/2023	2,831	325	348	562	N/A
6/30/2023	2,682	270	369	549	N/A
3/31/2023	2,595	286	333	519	N/A
12/31/2022	2,488	274	267	442	N/A
9/30/2022	2,370	305	214	367	N/A
6/30/2022	2,313	311	122	260	N/A
3/31/2022	2,220	289	166	290	N/A
12/31/2021	2,105	259	246	362	N/A
9/30/2021	1,935	202	178	305	N/A
6/30/2021	1,742	206	240	363	N/A
3/31/2021	1,498	165	110	215	N/A
12/31/2020	1,318	132	54	183	N/A
9/30/2020	1,257	150	82	211	N/A
6/30/2020	1,207	123	35	198	N/A
3/31/2020	1,246	131	33	244	N/A
12/31/2019	1,252	147	106	307	N/A
9/30/2019	1,227	110	88	290	N/A
6/30/2019	1,206	115	43	264	N/A
3/31/2019	1,193	119	5	255	N/A
12/31/2018	1,181	142	-51	204	N/A
9/30/2018	1,189	172	-158	184	N/A
6/30/2018	1,203	217	N/A	253	N/A
3/31/2018	1,218	268	N/A	297	N/A
12/31/2017	1,212	295	N/A	353	N/A
9/30/2017	1,202	284	N/A	457	N/A
6/30/2017	1,180	268	N/A	387	N/A
3/31/2017	1,181	252	N/A	382	N/A
12/31/2016	1,163	225	N/A	343	N/A
9/30/2016	1,122	228	N/A	244	N/A
6/30/2016	1,073	194	N/A	261	N/A
3/31/2016	1,030	175	N/A	233	N/A
12/31/2015	985	165	N/A	214	N/A
9/30/2015	948	161	N/A	204	N/A
6/30/2015	917	156	N/A	168	N/A
3/31/2015	892	154	N/A	151	N/A
12/31/2014	859	147	N/A	149	N/A
9/30/2014	831	149	N/A	137	N/A
6/30/2014	805	149	N/A	138	N/A
3/31/2014	773	138	N/A	108	N/A
12/31/2013	750	137	N/A	102	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 4004 의 연간 예상 수익 증가율( 14.9% )이 saving rate( 14.7% 보다 높습니다. ).

수익 vs 시장: 4004 의 연간 수익( 14.9% ) SA 시장( 5.9% 보다 빠르게 성장할 것으로 예상됩니다. 5.9% 연간).

고성장 수익: 4004 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 4004 의 수익(연간 11.9% ) SA 시장( -0.6% 보다 빠르게 성장할 것으로 예상됩니다. -0.6% 연간).

고성장 수익: 4004 의 수익(연간 11.9% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 4004 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 17.2 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/22 15:06
장 마감 주가	2024/12/22 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Dallah Healthcare Company 22 애널리스트 중 9 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Ibrahim Elaiwat	Aljazira Capital Company
Jassim Al-Jubran	Aljazira Capital Company
Rim Ben Salah Gharbi	AlphaMena

Dallah Healthcare 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Dallah Healthcare Company (TADAWUL:4004) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Consensus EPS estimates increase by 18%

Consensus EPS estimates increase by 22%

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 17%

Price target increased to ر.س118

Recent updates

With EPS Growth And More, Dallah Healthcare (TADAWUL:4004) Makes An Interesting Case

Third quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Second quarter dividend of ر.س0.50 announced

Some Shareholders Feeling Restless Over Dallah Healthcare Company's (TADAWUL:4004) P/E Ratio

The Return Trends At Dallah Healthcare (TADAWUL:4004) Look Promising

Do Dallah Healthcare's (TADAWUL:4004) Earnings Warrant Your Attention?

Upcoming dividend of ر.س0.50 per share

Dallah Healthcare Company (TADAWUL:4004) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Second quarter 2024 earnings released: EPS: ر.س1.15 (vs ر.س0.54 in 2Q 2023)

Dividend of ر.س0.50 announced

Dallah Healthcare Company announces Quarterly dividend, payable on September 08, 2024

The Price Is Right For Dallah Healthcare Company (TADAWUL:4004)

Investors Will Want Dallah Healthcare's (TADAWUL:4004) Growth In ROCE To Persist

Dallah Healthcare Company, Annual General Meeting, Jun 13, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations

Consensus EPS estimates increase by 18%

We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease

Full year 2023 earnings: EPS exceeds analyst expectations

What You Can Learn From Dallah Healthcare Company's (TADAWUL:4004) P/E

Returns On Capital At Dallah Healthcare (TADAWUL:4004) Have Hit The Brakes

Upcoming dividend of ر.س0.50 per share at 1.2% yield

Dallah Healthcare Co. Announces the Distribution of Cash Dividends for the Fourth Quarter of 2023, Payable on 30 January 2024

Third quarter 2023 earnings released: EPS: ر.س1.01 (vs ر.س0.49 in 3Q 2022)

Consensus EPS estimates increase by 22%

Dallah Healthcare (TADAWUL:4004) Has More To Do To Multiply In Value Going Forward

Upcoming dividend of ر.س0.50 per share at 1.6% yield

Second quarter 2023 earnings released: EPS: ر.س0.54 (vs ر.س0.77 in 2Q 2022)

Consensus EPS estimates fall by 14%

Dallah Healthcare (TADAWUL:4004) Is Reinvesting At Lower Rates Of Return

New minor risk - Dividend sustainability

Upcoming dividend of ر.س0.50 per share at 1.2% yield

Consensus EPS estimates fall by 17%

Returns On Capital Signal Tricky Times Ahead For Dallah Healthcare (TADAWUL:4004)

Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?

Dallah Healthcare Company (SASE:4004) completed the acquisition of an additional 18.98% stake in International Medical Centre.

Dallah Healthcare Co. Announces the Distribution of Cash Dividends for Second Half of the Fiscal Year 2022, Payable on December 29, 2022

Dallah Healthcare (TADAWUL:4004) Will Want To Turn Around Its Return Trends

Dallah Healthcare Company Approves Resignation of Fahad Bin Abdulaziz Al-Rabiah as Board of Directors and Compensation and Remuneration Committee

Less than half of directors are independent

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Dallah Healthcare Company Approves Board Appointments

We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease

Price target increased to ر.س118

Investor sentiment improved over the past week

Dallah Healthcare Company, Annual General Meeting, Oct 19, 2022

Dallah Healthcare Co. Announces the Distribution of Cash Dividends for First Half of 2022

Now 20% undervalued

Calculating The Intrinsic Value Of Dallah Healthcare Company (TADAWUL:4004)

Second quarter 2022 earnings released: EPS: ر.س0.77 (vs ر.س0.53 in 2Q 2021)

Dallah Healthcare (TADAWUL:4004) Has Some Way To Go To Become A Multi-Bagger

Now 21% undervalued after recent price drop

Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching

Price target increased to ر.س103

Consensus forecasts updated

Industry Analysts Just Upgraded Their Dallah Healthcare Company (TADAWUL:4004) Revenue Forecasts By 10%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Dallah Healthcare Company, Annual General Meeting, Jun 12, 2022

Calculating The Fair Value Of Dallah Healthcare Company (TADAWUL:4004)

Less than half of directors are independent

Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching

Consensus forecasts updated

Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively

Price target increased to ر.س77.36

Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2021 earnings released: EPS ر.س0.96 (vs ر.س0.63 in 3Q 2020)

Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively

Upcoming dividend of ر.س0.50 per share